Grufity logoGrufity logo

Zoetis Inc Stock Research

ZTS

166.31USD+2.74(+1.68%)Market Closed

Market Summary

USD166.31+2.74
Market Closed
1.68%

ZTS Alerts

ZTS Stock Price

ZTS RSI Chart

ZTS Valuation

Market Cap

77.1B

Price/Earnings (Trailing)

36.49

Price/Sales (Trailing)

9.55

EV/EBITDA

22.01

Price/Free Cashflow

58.17

ZTS Price/Sales (Trailing)

ZTS Profitability

EBT Margin

32.87%

Return on Equity

47.99%

Return on Assets

14.19%

Free Cashflow Yield

1.72%

ZTS Fundamentals

ZTS Revenue

Revenue (TTM)

8.1B

Revenue Y/Y

3.71%

Revenue Q/Q

1.9%

ZTS Earnings

Earnings (TTM)

2.1B

Earnings Y/Y

11.35%

Earnings Q/Q

-12.85%

Price Action

52 Week Range

124.15200.17
(Low)(High)

Last 7 days

-3.0%

Last 30 days

0.3%

Last 90 days

10.0%

Trailing 12 Months

-13.0%

ZTS Financial Health

Current Ratio

2.37

ZTS Investor Care

Dividend Yield

0.81%

Dividend/Share (TTM)

1.35

Buy Backs (1Y)

1.85%

Diluted EPS (TTM)

4.49

Peers (Alternatives to Zoetis)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
JNJ
404.8B
94.9B
 -5.16% -10.64%
22.56
4.26
 1.25% -14.07%
LLY
296.8B
28.5B
 -5.67% 20.74%
47.53
10.4
 0.79% 11.88%
MRK
272.8B
59.3B
 -1.75% 40.02%
17.88
4.63
 21.72% 11.27%
PFE
226.4B
100.3B
 -8.43% -20.95%
7.22
2.26
 23.43% 42.74%
BMY
142.7B
46.2B
 -7.78% -1.12%
22.55
3.09
 -0.49% -9.54%
MID-CAP
PRGO
4.8B
4.5B
 -0.20% -5.41%
-34.17
1.08
 7.56% -104.06%
RETA
3.3B
2.2M
 105.10% 171.03%
-10.52
1.5K
 -80.71% -4.88%
SMALL-CAP
SUPN
1.9B
667.2M
 -9.96% 17.66%
31.57
2.87
 15.09% 13.64%
TLRY
1.6B
602.5M
 -17.77% -52.80%
-2.74
2.63
 18.18% -18.59%
CGC
991.7M
478.9M
 -11.35% -65.42%
-0.32
2.07
 -31.50% -634.70%
INVA
792.9M
285.2M
 -7.22% -37.95%
3.6
2.78
 -27.21% -40.28%
CRON
768.8M
114.5M
 -15.28% -37.42%
-4.56
6.72
 27.90% 57.40%
ACRS
541.5M
29.8M
 -40.95% -47.43%
-6.23
18.2
 340.05% 4.35%
OCUL
400.7M
51.5M
 -2.49% -0.39%
-5.64
7.78
 18.32% -984.05%
ENDP
94.1M
2.3B
 -43.99% -88.43%
-0.03
0.04
 -22.53% -376.66%

Financials for Zoetis

Income Statement (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue0.9%8,0808,0077,9957,8917,776
  S&GA Expenses-3.8%2,0092,0882,0912,0572,001
EBITDA3.0%3,3423,2463,2363,201-
EBITDA Margin2.0%0.41*0.41*0.41*0.41*-
Earnings Before Taxes3.3%2,6562,5702,5622,5282,488
EBT Margin2.4%0.33*0.32*0.32*0.32*-
Interest Expenses3.8%221213216220224
Net Income2.3%2,1142,0672,0902,0732,037
Net Income Margin1.3%0.26*0.26*0.26*0.26*-
Free Cahsflow4.7%1,3261,2671,4291,607-
Balance Sheet
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets9.0%14,90013,67413,77013,86013,900
  Current Assets14.6%7,5066,5516,6516,8376,930
    Cash Equivalents42.8%3,5812,5072,6523,1353,485
  Inventory1.8%2,3452,3032,2052,0571,923
  Net PPE5.0%2,7532,6232,5592,4872,422
  Goodwill2.0%2,7462,6922,7202,6852,682
Liabilities16.8%10,5229,0129,1909,2029,356
  Current Liabilities10.0%3,1672,8803,0513,0341,797
.    Short Term Borrowings-33.3%2.003.002.00--
    LT Debt, Current0%1,3501,3501,3501,350-
    LT Debt, Non Current25.8%6,5525,2105,2215,2286,592
Shareholder's Equity-5.5%4,4054,6634,5804,6584,543
  Retained Earnings1.6%8,6688,5338,0047,6287,186
  Additional Paid-In Capital1.4%1,0881,0731,0591,0461,068
Accumulated Depreciation2.9%2,2972,2322,1932,1412,072
Shares Outstanding-0.6%464466469471473
Minority Interest-100.0%-2.00-1.00--1.00
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations3.4%1,9121,8501,9772,1222,213
  Share Based Compensation3.3%62.0060.0060.0061.0058.00
Cashflow From Investing-50.4%-883-587-577-513-458
Cashflow From Financing54.8%-904-1,998-2,388-2,068-1,862
  Buy Backs14.9%1,5941,3871,208923743

Risks for ZTS

What is the probability of a big loss on ZTS?

41.1%

Probability that Zoetis stock will be more than 20% underwater in next one year

35.8%

Probability that Zoetis stock will be more than 30% underwater in next one year.

4.2%

Probability that Zoetis stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does ZTS drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Zoetis was unfortunately bought at previous high price.

Drawdowns

Returns for ZTS

Cumulative Returns on ZTS

18.0%

10-Year Cumulative Returns

22.9%

7-Year Cumulative Returns

14.8%

5-Year Cumulative Returns

9.9%

3-Year Cumulative Returns

What are the long-term rolling returns for ZTS?

FIve years rolling returns for Zoetis.

Annualized Returns

Which funds bought or sold ZTS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-15
B. Riley Wealth Advisors, Inc.
added
0.81
-15,995
4,046,000
 0.11%
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
reduced
-17.05
-33,582,900
152,763,000
 0.17%
2023-03-10
MATHER GROUP, LLC.
added
14.21
146,191
1,279,190
 0.03%
2023-03-08
Capital Asset Advisory Services LLC
reduced
-24.43
-174,023
607,977
 0.05%
2023-03-08
SHEETS SMITH WEALTH MANAGEMENT
unchanged
-
-2,413
220,587
 0.04%
2023-03-07
Great Lakes Retirement, Inc.
new
-
857,870
857,870
 0.22%
2023-03-06
Rockefeller Capital Management L.P.
reduced
-0.53
-621,000
36,013,000
 0.18%
2023-03-03
TIAA, FSB
added
11.8
2,071,170
21,816,200
 0.09%
2023-03-02
OLIVER LAGORE VANVALIN INVESTMENT GROUP
reduced
-6.17
-862
11,138
 0.01%
2023-03-02
LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA
new
-
4,129,050
4,129,050
 0.05%

1–10 of 47

Latest Funds Activity

Are funds buying ZTS calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own ZTS
No. of Funds

ZTS Alerts

Zoetis News

MarketBeat

Coldstream Capital Management Inc. Invests $910000 in Zoetis Inc ....

MarketBeat,
92 minutes ago

MarketBeat

DNB Asset Management AS Reduces Stake in Zoetis Inc. (NYSE:ZTS).

MarketBeat,
20 hours ago

Seeking Alpha

NFJ CEF: Non-Leveraged Hybrid Fund At A Wide Discount.

Seeking Alpha,
2 days ago

Nasdaq

First Week of May 19th Options Trading For Zoetis (ZTS).

Nasdaq,
2 days ago

Nasdaq

Top Research Reports for Nike, Salesforce & Zoetis.

Nasdaq,
3 days ago

Nasdaq

Guru Fundamental Report for ZTS.

Nasdaq,
3 days ago

Seeking Alpha

3 Awesome Dividend Growth Stocks To Buy During A Bear Market.

Seeking Alpha,
6 days ago

DirectorsTalk Interviews

Zoetis Inc. - Consensus Indicates Potential 28.8% Upside.

DirectorsTalk Interviews,
6 days ago

Marketscreener.com

Zoetis Named One of the World's Most Ethical Companies by Ethisphere.

Marketscreener.com,
6 days ago

MarketBeat

Bradley Mark J. Grows Position in Zoetis Inc. (NYSE:ZTS).

MarketBeat,
9 days ago

InvestorsObserver

Is Zoetis Inc (ZTS) Stock at the Top of the Drug Manufacturers - Specialty & Generic Industry?.

InvestorsObserver,
9 days ago

MarketBeat

Marietta Investment Partners LLC Sells 1227 Shares of Zoetis Inc ....

MarketBeat,
16 days ago

Benzinga

This Favorable Sign Appears On Zoetis's Chart - Zoetis (NYSE:ZTS).

Benzinga,
17 days ago

Yahoo Finance

Is Zoetis (ZTS) a Worthy Investment?.

Yahoo Finance,
19 days ago

Best Stocks

Cary Street Partners Investment Advisory LLC buys 3,985 Zoetis Inc ....

Best Stocks,
20 days ago

MarketBeat

BlackRock Inc. Sells 2257101 Shares of Zoetis Inc. (NYSE:ZTS).

MarketBeat,
21 days ago

Schedule 13G FIlings of Zoetis

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 09, 2023
vanguard group inc
7.91%
36,850,763
SC 13G/A
Feb 06, 2023
blackrock inc.
8.6%
40,082,444
SC 13G/A
Feb 03, 2022
blackrock inc.
8.5%
40,315,810
SC 13G/A
Feb 10, 2021
vanguard group inc
7.79%
37,023,889
SC 13G/A
Feb 01, 2021
blackrock inc.
8.6%
40,720,915
SC 13G/A
Feb 12, 2020
vanguard group inc
7.85%
37,400,083
SC 13G/A
Feb 06, 2020
blackrock inc.
8.7%
41,563,670
SC 13G/A

ZTS Fair Value

Zoetis fair value in different scenarios

The table shows the Fair Value estimates for Zoetis for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

67.03

-59.70%

82.21

-50.57%

106.10

-36.20%

134.03

-19.41%

160.78

-3.33%
Current Inflation

61.16

-63.23%

73.93

-55.55%

93.64

-43.70%

116.76

-29.79%

138.92

-16.47%
Very High Inflation

53.96

-67.55%

63.98

-61.53%

79.03

-52.48%

96.85

-41.77%

113.94

-31.49%

Historical Zoetis Fair Value Estimates

Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Zoetis

View All Filings
Date Filed Form Type Document
Feb 16, 2023
4
Insider Trading
Feb 14, 2023
4
Insider Trading
Feb 14, 2023
4
Insider Trading
Feb 14, 2023
4
Insider Trading
Feb 14, 2023
4
Insider Trading
Feb 14, 2023
4
Insider Trading
Feb 14, 2023
4
Insider Trading
Feb 14, 2023
4
Insider Trading
Feb 14, 2023
8-K
Current Report
Feb 14, 2023
4
Insider Trading

Latest Insider Trading transactions for ZTS

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-02-14
Lagano Roxanne
sold
-2,276,750
175
-13,010
executive vice president
2023-02-14
Lagano Roxanne
acquired
1,038,840
79.8496
13,010
executive vice president
2023-02-11
Polzer Robert J
acquired
-
-
631
executive vice president
2023-02-11
Driscoll Rimma
sold (taxes)
-42,274
158
-267
executive vice president
2023-02-11
Chen Heidi C.
acquired
-
-
5,140
executive vice president
2023-02-11
PECK KRISTIN C
sold (taxes)
-2,039,920
158
-12,884
chief executive officer
2023-02-11
PARENT LOUISE M
acquired
-
-
1,626
-
2023-02-11
Polzer Robert J
sold (taxes)
-34,040
158
-215
executive vice president
2023-02-11
Reed Willie M
acquired
-
-
1,626
-
2023-02-11
Chen Heidi C.
sold (taxes)
-287,844
158
-1,818
executive vice president

1–10 of 50

About Zoetis

Kristin C. Peck
www.zoetis.com
12100
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.

ZTS Income Statement

2022-12-31
CONSOLIDATED STATEMENTS OF INCOME - USD ($)
shares in Thousands, $ in Millions
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Income Statement [Abstract]   
Revenues$ 8,080$ 7,776$ 6,675
Costs and expenses:   
Cost of Sales[1]2,4542,3032,057
Selling, general and administrative expenses[1]2,0092,0011,726
Research and development expenses[1]539508463
Amortization of intangible assets150161160
Total Restructuring charges and certain acquisition-related costs114325
Interest expense, net of capitalized interest221224231
Other (income)/deductions––net404817
Income before provision for taxes on income[2]2,6562,4881,996
Provision for taxes on income545454360
Net income before allocation to noncontrolling interests2,1112,0341,636
Less: Net loss attributable to noncontrolling interests(3)(3)(2)
Net income attributable to Zoetis Inc.$ 2,114$ 2,037$ 1,638
Earnings per share attributable to Zoetis Inc. stockholders:   
Basic (in dollars per share)$ 4.51$ 4.29$ 3.44
Diluted (in dollars per share)$ 4.49$ 4.27$ 3.42
Weighted-average common shares outstanding:   
Basic (in shares)468,891474,348475,502
Diluted (in shares)470,385476,717478,569
Dividends declared per common share$ 1.350$ 1.075$ 0.850
[1]Exclusive of amortization of intangible assets, except as disclosed in Note 3. Significant Accounting Policies—Amortization of Intangible Assets, Depreciation and Certain Long-Lived Assets.
[2]Defined as income before provision for taxes on income.

ZTS Balance Sheet

2022-12-31
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Millions
Dec. 31, 2022
Dec. 31, 2021
Assets  
Cash and cash equivalents[1]$ 3,581$ 3,485
Accounts receivable, less allowance for doubtful accounts of $19 in 2022 and $17 in 20211,2151,133
Inventories2,3451,923
Other current assets365389
Total current assets7,5066,930
Property, plant and equipment, less accumulated depreciation of $2,297 in 2022 and $2,072 in 20212,7532,422
Operating lease right of use assets220181
Goodwill2,7462,682
Identifiable intangible assets, less accumulated amortization1,3801,474
Noncurrent deferred tax assets173100
Other noncurrent assets147111
Total assets14,92513,900
Liabilities and Equity  
Short-term borrowings20
Current portion of long-term debt1,3500
Accounts payable405436
Dividends payable174154
Accrued expenses682710
Accrued compensation and related items300392
Income taxes payable15738
Other current liabilities9767
Total current liabilities3,1671,797
Long-term debt, net of discount and issuance costs6,5526,592
Noncurrent deferred tax liabilities142320
Operating lease liabilities186151
Other taxes payable258257
Other noncurrent liabilities217239
Total liabilities10,5229,356
Common stock, $0.01 par value: 6,000,000,000 authorized, 501,891,243 and 501,891,243 shares issued; 463,808,059 and 472,574,090 shares outstanding at December 31, 2022 and 2021, respectively55
Treasury stock, at cost, 38,083,184 and 29,317,153 shares of common stock at December 31, 2022 and 2021, respectively(4,539)(2,952)
Additional paid-in capital1,0881,068
Retained earnings8,6687,186
Accumulated other comprehensive loss(817)(764)
Stockholders' Equity Attributable to Parent4,4054,543
Stockholders' Equity Attributable to Noncontrolling Interest(2)1
Total equity4,4034,544
Total liabilities and equity$ 14,925$ 13,900
[1]As of December 31, 2022 and 2021, includes $4 million and $3 million, respectively, of restricted cash.